SrasV1, PascalFrancis, Checkpoint, bibRecord, 000658

Emerging infectious agents

Identifieur interne : 000658 ( PascalFrancis/Checkpoint ); précédent : 000657; suivant : 000659

Emerging infectious agents

Auteurs : D. A. Leiby [États-Unis]

Source :

Developments in biologicals [ 1424-6074 ] ; 2005.

RBID : Pascal:05-0368719

Descripteurs français

Pascal (Inist)
- Trypanosoma cruzi, Virus West Nile, Babesia microti, Homme, Syndrome respiratoire aigu sévère, Receveur, Sang, Transfusion, Sécurité transfusionnelle, Adaptation, Transmission, Toxicité, Maladie émergente.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adaptation, Babesia microti, Blood, Emerging disease, Human, Recipient, Severe acute respiratory syndrome, Toxicity, Transfusion, Transfusion safety, Transmission, Trypanosoma cruzi, West Nile virus.

Abstract

As new agents of infectious disease continue to emerge and old antagonists re-emerge, it is clear that the war on infectious disease is far from over. Indeed, the appearance of SARS during the past year is the latest example of the continuing challenges posed by agents of infectious disease. Emerging agents are threats not only to the general population, but also to recipients of blood transfusions. Today a variety of emerging agents are of concern to transfusion safety including Trypanosoma cruzi, West Nile virus, and Babesia microti to name but a few. These and other emerging agents have arisen or have been introduced partly through changes in donor demographics, international travel, microbial adaptations, land use, and human behaviour. Unfortunately, for many of these agents there is an absence of viable tests or other sound interventions to prevent their transmission at this time.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000625
to stream PascalFrancis, to step Curation: 000365

Links to Exploration step

Pascal:05-0368719

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Emerging infectious agents</title>
<author><name sortKey="Leiby, D A" sort="Leiby, D A" uniqKey="Leiby D" first="D. A." last="Leiby">D. A. Leiby</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Transmissible Diseases Department, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0368719</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0368719 INIST</idno>
<idno type="RBID">Pascal:05-0368719</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000625</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000365</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000658</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000658</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Emerging infectious agents</title>
<author><name sortKey="Leiby, D A" sort="Leiby, D A" uniqKey="Leiby D" first="D. A." last="Leiby">D. A. Leiby</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Transmissible Diseases Department, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Developments in biologicals</title>
<title level="j" type="abbreviated">Dev. biol.</title>
<idno type="ISSN">1424-6074</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Developments in biologicals</title>
<title level="j" type="abbreviated">Dev. biol.</title>
<idno type="ISSN">1424-6074</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptation</term>
<term>Babesia microti</term>
<term>Blood</term>
<term>Emerging disease</term>
<term>Human</term>
<term>Recipient</term>
<term>Severe acute respiratory syndrome</term>
<term>Toxicity</term>
<term>Transfusion</term>
<term>Transfusion safety</term>
<term>Transmission</term>
<term>Trypanosoma cruzi</term>
<term>West Nile virus</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Trypanosoma cruzi</term>
<term>Virus West Nile</term>
<term>Babesia microti</term>
<term>Homme</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Receveur</term>
<term>Sang</term>
<term>Transfusion</term>
<term>Sécurité transfusionnelle</term>
<term>Adaptation</term>
<term>Transmission</term>
<term>Toxicité</term>
<term>Maladie émergente</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As new agents of infectious disease continue to emerge and old antagonists re-emerge, it is clear that the war on infectious disease is far from over. Indeed, the appearance of SARS during the past year is the latest example of the continuing challenges posed by agents of infectious disease. Emerging agents are threats not only to the general population, but also to recipients of blood transfusions. Today a variety of emerging agents are of concern to transfusion safety including Trypanosoma cruzi, West Nile virus, and Babesia microti to name but a few. These and other emerging agents have arisen or have been introduced partly through changes in donor demographics, international travel, microbial adaptations, land use, and human behaviour. Unfortunately, for many of these agents there is an absence of viable tests or other sound interventions to prevent their transmission at this time.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1424-6074</s0>
</fA01>
<fA03 i2="1"><s0>Dev. biol.</s0>
</fA03>
<fA05><s2>120</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>Emerging infectious agents</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>ATS 2003 Symposium: Advances in transfusion safety, Bethesda, MD, USA, June 4-6, 2003</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>LEIBY (D. A.)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>VYAS (G. N.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>WILLIAMS (A. E.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Transmissible Diseases Department, Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>University of San Francisco</s1>
<s2>San Francisco, CA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>Food and Drug Administration</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA18 i1="01" i2="1"><s1>U.S. Food and Drug Administration</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<s9>org-cong.</s9>
</fA18>
<fA18 i1="02" i2="1"><s1>AABB American Association of Blood Banks</s1>
<s3>USA</s3>
<s9>org-cong.</s9>
</fA18>
<fA18 i1="03" i2="1"><s1>National Institute of Health NIH. National Heart, Lung, and Blood Institute</s1>
<s2>Bethesda, MD</s2>
<s3>USA</s3>
<s9>org-cong.</s9>
</fA18>
<fA18 i1="04" i2="1"><s1>U.S. Department of Defense</s1>
<s3>USA</s3>
<s9>org-cong.</s9>
</fA18>
<fA18 i1="05" i2="1"><s1>International Association for Biologicals (IABs)</s1>
<s2>Acacias-Geneva</s2>
<s3>CHE</s3>
<s9>org-cong.</s9>
</fA18>
<fA20><s1>11-15</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13557</s2>
<s5>354000131443740020</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>15 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0368719</s0>
</fA47>
<fA60><s1>P</s1>
<s2>C</s2>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Developments in biologicals</s0>
</fA64>
<fA66 i1="01"><s0>CHE</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>As new agents of infectious disease continue to emerge and old antagonists re-emerge, it is clear that the war on infectious disease is far from over. Indeed, the appearance of SARS during the past year is the latest example of the continuing challenges posed by agents of infectious disease. Emerging agents are threats not only to the general population, but also to recipients of blood transfusions. Today a variety of emerging agents are of concern to transfusion safety including Trypanosoma cruzi, West Nile virus, and Babesia microti to name but a few. These and other emerging agents have arisen or have been introduced partly through changes in donor demographics, international travel, microbial adaptations, land use, and human behaviour. Unfortunately, for many of these agents there is an absence of viable tests or other sound interventions to prevent their transmission at this time.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A01D</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C09</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Trypanosoma cruzi</s0>
<s2>NS</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Trypanosoma cruzi</s0>
<s2>NS</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Trypanosoma cruzi</s0>
<s2>NS</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Virus West Nile</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>West Nile virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>West Nile virus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Babesia microti</s0>
<s2>NS</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Babesia microti</s0>
<s2>NS</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Babesia microti</s0>
<s2>NS</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Homme</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Human</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Receveur</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Recipient</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Receptor</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Sang</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Blood</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Sangre</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Transfusion</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Transfusion</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Transfusión</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Sécurité transfusionnelle</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Transfusion safety</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Seguridad de la transfusión</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Adaptation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Adaptation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Adaptación</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Transmission</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Transmission</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Transmisión</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Maladie émergente</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Emerging disease</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Enfermedad emergente</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Kinetoplastida</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Kinetoplastida</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Kinetoplastida</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Protozoa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus groupe encéphalite japonaise</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Japanese encephalitis group virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Japanese encephalitis group virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Flavivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Flaviviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Apicomplexa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Apicomplexa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Apicomplexa</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>255</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
<pR><fA30 i1="01" i2="1" l="ENG"><s1>Advances in transfusion safety. Symposium</s1>
<s3>Bethesda, MD USA</s3>
<s4>2003-06-04</s4>
</fA30>
</pR>
</standard>
</inist>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Leiby, D A" sort="Leiby, D A" uniqKey="Leiby D" first="D. A." last="Leiby">D. A. Leiby</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000658 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000658 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:05-0368719
   |texte=   Emerging infectious agents
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Emerging infectious agents

Emerging infectious agents

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri